进展

订阅

MedSci主页 / 所有栏目 / 进展

赋予ALK抑制剂耐药性的 肺癌中EML4-ALK突变

2010-11-19 MedSci原创 MedSci原创

肺癌ALK
关注

　　概述 　　EML4（棘皮动物微管相关蛋白样4）-ALK（间变性淋巴瘤激酶）融合型酪氨酸激酶是一种癌蛋白，可见于4%～5%的非小细胞肺癌中，并且有关ALK特异性抑制剂治疗此类肿瘤的临床试验目前正在进行中。在此，我们报告在肿瘤细胞中发现的EML4-ALK的激酶功能区内的两个继发突变，这些肿瘤细胞是从1例用ALK抑制剂治疗的复发期病人中分离得到的。每个突变在该肿瘤的亚克隆中独立出现，并且使肿瘤对

　　概述

　　EML4（棘皮动物微管相关蛋白样4）-ALK（间变性淋巴瘤激酶）融合型酪氨酸激酶是一种癌蛋白，可见于4%～5%的非小细胞肺癌中，并且有关ALK特异性抑制剂治疗此类肿瘤的临床试验目前正在进行中。在此，我们报告在肿瘤细胞中发现的EML4-ALK的激酶功能区内的两个继发突变，这些肿瘤细胞是从1例用ALK抑制剂治疗的复发期病人中分离得到的。每个突变在该肿瘤的亚克隆中独立出现，并且使肿瘤对2种不同的ALK抑制剂产生了明显的耐药。

　　（N Engl J Med 2010; 363:1734-9. October 28, 2010）

免费全文下载：http://www.nejm.org/doi/pdf/10.1056/NEJMoa1007478

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851069, encodeId=658f18510695e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Jun 22 13:59:00 CST 2011, time=2011-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779685, encodeId=108d1e79685f4, content=<a href='/topic/show?id=514e232078' target=_blank style='color:#2F92EE;'>#ALK突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2320, encryptionId=514e232078, topicName=ALK突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Fri May 27 20:59:00 CST 2011, time=2011-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442706, encodeId=4c941442e06a9, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sun Nov 21 13:59:00 CST 2010, time=2010-11-21, status=1, ipAttribution=)]
    2011-06-22 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1851069, encodeId=658f18510695e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Jun 22 13:59:00 CST 2011, time=2011-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779685, encodeId=108d1e79685f4, content=<a href='/topic/show?id=514e232078' target=_blank style='color:#2F92EE;'>#ALK突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2320, encryptionId=514e232078, topicName=ALK突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Fri May 27 20:59:00 CST 2011, time=2011-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442706, encodeId=4c941442e06a9, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sun Nov 21 13:59:00 CST 2010, time=2010-11-21, status=1, ipAttribution=)]
    2011-05-27 zhao4616

    #ALK突变#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851069, encodeId=658f18510695e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed Jun 22 13:59:00 CST 2011, time=2011-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779685, encodeId=108d1e79685f4, content=<a href='/topic/show?id=514e232078' target=_blank style='color:#2F92EE;'>#ALK突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2320, encryptionId=514e232078, topicName=ALK突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Fri May 27 20:59:00 CST 2011, time=2011-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442706, encodeId=4c941442e06a9, content=<a href='/topic/show?id=d6bc231956' target=_blank style='color:#2F92EE;'>#ALK抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2319, encryptionId=d6bc231956, topicName=ALK抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68704968601, createdName=12498cf9m36(暂无昵称), createdTime=Sun Nov 21 13:59:00 CST 2010, time=2010-11-21, status=1, ipAttribution=)]
    2010-11-21 12498cf9m36(暂无昵称)

    #ALK抑制剂#

    0

相关资讯

随机、双盲双模拟、平行对照、多中心评价埃克替尼和吉非替尼治疗既往接受过一个或两个化疗的局部晚期或转移的非小细胞肺癌患者的疗效和安全性III 期临床研究

　　报告者：中国医学科学院肿瘤医院孙燕  　　时间：9 月17 日09:30～09:50  　　地点：16 区1 层大宴会厅 　　盐酸埃克替尼是一种口服表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），属国家Ⅰ类新药，化学结构上和吉非替尼及厄洛替尼相似。本研究主要目的为比较埃克替尼与吉非替尼治疗晚期非小细胞肺癌（NSCLC）患者